Go offline with the Player FM app!
The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott
Manage episode 509064332 series 2739469
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and outcomes research (HEOR), and not just with patients and commercial payers. HEOR, viewed as a strategic lever as opposed to a compliance exercise, can help answer investor questions about market differentiation, pricing pathways, and real world product validation. Abbott talks about the value of cost-of-illness studies, burden-of-disease analyses, and payer landscape assessments, and how AI, real world evidence, and patient-centered research can improve drug and trial design and accelerate market access.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Introduction to HEOR and ISPOR (00:00:00)
2. Building an HEOR Program from Scratch (00:08:39)
3. HEOR Value for Investors and Startups (00:15:07)
4. Emerging Trends: AI and Patient Centricity (00:27:13)
5. Real-World Evidence and Policy Impact (00:39:05)
6. Final Thoughts on Healthcare Value (00:51:49)
274 episodes
Manage episode 509064332 series 2739469
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and outcomes research (HEOR), and not just with patients and commercial payers. HEOR, viewed as a strategic lever as opposed to a compliance exercise, can help answer investor questions about market differentiation, pricing pathways, and real world product validation. Abbott talks about the value of cost-of-illness studies, burden-of-disease analyses, and payer landscape assessments, and how AI, real world evidence, and patient-centered research can improve drug and trial design and accelerate market access.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Introduction to HEOR and ISPOR (00:00:00)
2. Building an HEOR Program from Scratch (00:08:39)
3. HEOR Value for Investors and Startups (00:15:07)
4. Emerging Trends: AI and Patient Centricity (00:27:13)
5. Real-World Evidence and Policy Impact (00:39:05)
6. Final Thoughts on Healthcare Value (00:51:49)
274 episodes
ทุกตอน
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.